The historical rank and industry rank for Lucid Diagnostics's Net Cash per Share or its related term are showing as below:
During the past 6 years, the highest Price-to-Net-Cash Ratio of Lucid Diagnostics was 4.25. The lowest was 3.81. And the median was 4.03.
LUCD's Price-to-Net-Cash is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 7.59 * Ranked among companies with meaningful Price-to-Net-Cash only.
Lucid Diagnostics Net Cash per Share Historical Data
The historical data trend for Lucid Diagnostics's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lucid Diagnostics's Net Cash per Share
For the Medical Devices subindustry, Lucid Diagnostics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lucid Diagnostics's Price-to-Net-Cash Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Lucid Diagnostics's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Lucid Diagnostics's Net Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lucid Diagnostics (NAS:LUCD) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Lucid Diagnostics Net Cash per Share Related Terms
Thank you for viewing the detailed overview of Lucid Diagnostics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LUCD has been successfully added to your 